11 May 2019 - The head of Australian drug company Specialised Therapeutics, Carlo Montagner, has warned that Bill Shorten’s cancer policy will not hit its target unless he overhauls the process to reimburse life saving treatments and puts a time frame on listing recommended drugs.

Mr Montagner said while it was a great “catch cry” to say all cancer drugs recommended for reimbursement would be ­approved by a Labor government, the approval process needed reviewing because it was delaying access to much-needed treatments.

“What would be more reassuring would be if Bill Shorten gave an actual time frame and said if the Pharmaceutical Benefits Advisory Committee recommended a drug, he would list it in six months,” he said.

Read The Australian article